Skip to main content

Advertisement

SpringerLink
Log in

Impact of Nesiritide on Renal Function and Mortality in Patients Suffering from Heart Failure

  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

Introduction

Acutely decompensated congestive heart failure is a major public health problem, with constantly rising prevalence, morbidity, mortality and need for hospitalization in both America and Europe. In 2001, the FDA approved the use of the drug nesiritide, which is a recombinant form of human brain or B-type natriuretic peptide (BNP) for the treatment of acutely decompensated congestive heart failure. In 2005, suspicions arose that nesiritide may worsen renal function and increase the risk of short term mortality when given to patients with acutely decompensated heart failure.

Methods

The present study reviews the recent literature with respect to the risk of deterioration in renal function and survival after the use of nesiritide in these patients.

Results

Administration of nesiritide may be considered for the treatment of heart failure and especially in patients with dyspnea at rest or with minimal activity.

Conclusion

Extreme caution is required when using nesiritide in patients with both heart failure and concurrent morbidities such as renal dysfunction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bleumink GS, Knetsch AM, Sturkenboom MC, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J. 2004;25:1614–9.

    Article  PubMed  Google Scholar 

  2. Mills RM, LeJemtel TH, Horton DP, et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol. 1999;34:155–62.

    Article  PubMed  CAS  Google Scholar 

  3. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000;343:246–53.

    Article  PubMed  CAS  Google Scholar 

  4. Yoshimura M, Yasue H, Morita E, et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 1991;84:1581–8.

    PubMed  CAS  Google Scholar 

  5. Holmes SJ, Espiner EA, Richards AM, Yandle TG, Frampton C. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab. 1993;76:91–6.

    Article  PubMed  CAS  Google Scholar 

  6. van der Zander K, Houben AJ, Kroon AA, de Leeuw PW. Effects of brain natriuretic peptide on forearm vasculature: comparison with atrial natriuretic peptide. Cardiovasc Res. 1999;44:595–600.

    Article  PubMed  Google Scholar 

  7. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005;111:1487–91.

    Article  PubMed  CAS  Google Scholar 

  8. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005;293:1900–5.

    Article  PubMed  CAS  Google Scholar 

  9. Hauptman PJ, Schnitzler MA, Swindle J, Burroughs TE. Use of nesiritide before and after publications suggesting drug-related risks in patients with acute decompensated heart failure. JAMA 2006;296:1877–84.

    Article  PubMed  CAS  Google Scholar 

  10. Witteles RM, Kao D, Christopherson D, et al. Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol. 2007;50:1835–40.

    Article  PubMed  CAS  Google Scholar 

  11. Arora S, Clarke K, Srinivasan V, Gradman A. Effect of nesiritide on renal function in patients admitted for decompensated heart failure. QJM 2007;100:699–706.

    Article  PubMed  CAS  Google Scholar 

  12. Wang DJ, Dowling TC, Meadows D, et al. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation 2004;110:1620–5.

    Article  PubMed  CAS  Google Scholar 

  13. Chen HH, Sundt TM, Cook DJ, Heublein DM, Burnett JC Jr. Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary-bypass surgery: a double-blind placebo-controlled pilot study. Circulation 2007;116:I134–8.

    Article  PubMed  CAS  Google Scholar 

  14. Mentzer RM Jr, Oz MC, Sladen RN, et al. NAPA Investigators. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA Trial. J Am Coll Cardiol. 2007;49:716–26.

    Article  PubMed  CAS  Google Scholar 

  15. Miller AH, Nazeer S, Pepe P, Estes B, Gorman A, Yancy CW. Acutely decompensated heart failure in a county emergency department: a double-blind randomized controlled comparison of nesiritide versus placebo treatment. Ann Emerg Med. 2008;51:571–8.

    Article  PubMed  Google Scholar 

  16. Owan TE, Chen HH, Frantz RP, et al. The effects of nesiritide on renal function and diuretic responsiveness in acutely decompensated heart failure patients with renal dysfunction. J Card Fail. 2008;14:267–75.

    Article  PubMed  CAS  Google Scholar 

  17. Butler J, Emerman C, Peacock WF, Mathur VS, Young JB. VMAC study investigators. The efficacy and safety of B-type natriuretic peptide (nesiritide) in patients with renal insufficiency and acutely decompensated congestive heart failure. Nephrol Dial Transplant. 2004;19:391–9.

    Article  PubMed  CAS  Google Scholar 

  18. Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation 1996;94:3184–9.

    PubMed  CAS  Google Scholar 

  19. Iglesias J, Hom D, Antoniotti M, Ayoub S, Levine JS. Predictors of worsening renal function in adult patients with congestive heart failure receiving recombinant human B-type brain natriuretic peptide (nesiritide). Nephrol Dial Transplant. 2006;21:3458–65.

    Article  PubMed  CAS  Google Scholar 

  20. Velazquez EJ, Francis GS, Armstrong PW, et al. VALIANT registry. An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry. Eur Heart J. 2004;25:1911–9.

    Article  PubMed  Google Scholar 

  21. D’Souza SP, Yellon DM, Martin C, et al. B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening. Am J Physiol Heart Circ Physiol. 2003;284:H1592–600.

    PubMed  Google Scholar 

  22. Ren B, Shen Y, Shao H, Qian J, Wu H, Jing H. Brain natriuretic peptide limits myocardial infarct size dependent of nitric oxide synthase in rats. Clin Chim Acta. 2007;377:83–7.

    Article  PubMed  CAS  Google Scholar 

  23. Hillock RJ, Frampton CM, Yandle TG, Troughton RW, Lainchbury JG, Richards AM. B-type natriuretic peptide infusions in acute myocardial infarction. Heart 2008;94:617–22.

    Article  PubMed  CAS  Google Scholar 

  24. Kurien S, Warfield KT, Wood CM, Miller WL. Effects of standard heart failure therapy and concomitant treatment with intravenous furosemide or inotropes (dobutamine, dopamine, and/or milrinone) on renal function and mortality in patients treated with nesiritide. Am J Cardiol. 2006;98:1627–30.

    Article  PubMed  CAS  Google Scholar 

  25. Yancy CW, Saltzberg MT, Berkowitz RL, et al. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial). Am J Cardiol. 2004;94:595–601.

    Article  PubMed  CAS  Google Scholar 

  26. Yancy CW, Singh A. Potential applications of outpatient nesiritide infusions in patients with advanced heart failure and concomitant renal insufficiency (from the Follow-Up Serial Infusions of Nesiritide [FUSION I] trial). Am J Cardiol. 2006;98:226–9.

    Article  PubMed  CAS  Google Scholar 

  27. Cleland JG, Coletta AP, Clark AL. Clinical trials update from the American College of Cardiology 2007: ALPHA, EVEREST, FUSION II, VALIDD, PARR-2, REMODEL, SPICE, COURAGE, COACH, REMADHE, pro-BNP for the evaluation of dyspnoea and THIS-diet. Eur J Heart Fail. 2007;9:740–5.

    Article  PubMed  Google Scholar 

  28. Miller WL, Kurien S, Warfield KT, Wood CM, Jaffe AS. Lack of association between worsening renal function and mortality in heart failure patients treated with nesiritide. Int J Cardiol. 2008;126:234–9.

    Article  PubMed  Google Scholar 

  29. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of dec.ompensated congestive heart failure: a randomized controlled trial. JAMA 2002;287:1531–40.

    Article  Google Scholar 

  30. Peacock WF, Emerman CL, Silver MA. Nesiritide added to standard care favorably reduces systolic blood pressure compared with standard care alone in patients with acute decompensated heart failure. Am J Emerg Med. 2005;23:327–31.

    Article  PubMed  Google Scholar 

  31. Arora RR, Venkatesh PK, Molnar J. Short and long-term mortality with nesiritide. Am Heart J. 2006;152:1084–90.

    Article  PubMed  CAS  Google Scholar 

  32. Burger AJ, Horton DP, LeJemtel T, et al. Prospective Randomized Evaluation of Cardiac Ectopy with Dobutamine or Natrecor Therapy Effect. of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J. 2002;144:1102–8.

    Article  PubMed  CAS  Google Scholar 

  33. Carroll RJ, Mulla ZD, Hauck LD, Westbrook A. Outcomes of patients hospitalized for acute decompensated heart failure: does nesiritide make a difference? BMC Cardiovasc Disord. 2007;7:37.

    Article  PubMed  Google Scholar 

  34. Sakr A, Hahn P, Donohue T, Ghantous A. Nesiritide in the initial management of acute decompensated congestive heart failure. Conn Med. 2008;72:517–23.

    PubMed  Google Scholar 

  35. Iglesias J, DePalma L, Hom D, Antoniotti M, Ayoub S, Levine J. Predictors of mortality in adult patients with congestive heart failure receiving nesiritide—Retrospective analysis showing a potential adverse interaction between nesiritide and acute renal dysfunction. Nephrol Dial Transplant. 2008;23:144–53.

    Article  PubMed  CAS  Google Scholar 

  36. DiDomenico RJ, Park HY, Southworth MR, et al. Guidelines for acute decompensated heart failure treatment. Ann Pharmacother. 2004;38:649–60.

    Article  PubMed  Google Scholar 

  37. Nieminen MS, Böhm M, Cowie MR, et al. ESC Committe for Practice Guideline (CPG). Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:384–416.

    Article  PubMed  Google Scholar 

  38. Burger AJ, Elkayam U, Neibaur MT, et al. Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy. Am J Cardiol. 2001;88:35–9.

    Article  PubMed  CAS  Google Scholar 

  39. Yancy CW, Krum H, Massie BM, et al. FUSION II Investigators. The Second Follow-up Serial Infusions of Nesiritide (FUSION II) trial for advanced heart failure: study rationale and design. Am Heart J. 2007;153:478–84.

    Article  PubMed  CAS  Google Scholar 

  40. Lewis EF, Johnson PA, Johnson W, Collins C, Griffin L, Stevenson LW. Preferences for quality of life or survival expressed by patients with heart failure. J Heart Lung Transplant. 2001;20:1016–24.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Experimental Surgery and Surgical Research “N.S.Christeas”, University of Athens, Medical School, 15B Agiou Thoma Street, 11527, Athens, Greece

    Ioannis D. Dontas, Theodoros Xanthos, Ismene Dontas, Pavlos Lelovas & Lila Papadimitriou

Authors
  1. Ioannis D. Dontas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Theodoros Xanthos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ismene Dontas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pavlos Lelovas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lila Papadimitriou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Theodoros Xanthos.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dontas, I.D., Xanthos, T., Dontas, I. et al. Impact of Nesiritide on Renal Function and Mortality in Patients Suffering from Heart Failure. Cardiovasc Drugs Ther 23, 221–233 (2009). https://doi.org/10.1007/s10557-009-6167-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10557-009-6167-6

Key words

Search

Navigation